An interventional study of Digital Weight Management Programme in Obesity and Obesity & Overweight, sponsored by Guy's and St Thomas' NHS Foundation Trust. Enrolling by invitation at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Guy's and St Thomas' NHS Foundation Trust · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 454 studies in Obesity with a site in United Kingdom — 94 open to participants now, 128 under way, 41 of them phase 3. Obesity · United Kingdom.
Among the 454 studies in Obesity with a site in United Kingdom, this one is the 65th largest by planned enrollment of the 372 interventional ones that give a count, is one of 34 that started in 2025, is one of 225 with no phase, reaches primary completion later than 64 of the 127 other live ones, and was the 399th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →94 of the 454 studies in Obesity with a site in United Kingdom are open now. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in United Kingdom, United States, Germany and 1 more country
Ages 45–65 · Women only
Boehringer Ingelheim · Sites in United Kingdom, United States, Germany and 1 more country
Ages 18+
Hoffmann-La Roche · Sites in United Kingdom, United States, Taiwan
Ages 40+
Elenzia · Sites in United Kingdom
Ages 25–65
StudySetGo · Sites in United Kingdom
Ages 30–65
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
454 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 36 · Phase 3 77 · Phase 4 12
First in 2001; this study’s year is marked. 34 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 580 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 66 across the 372 interventional studies, 130 across the 81 observational. Of the 272 that completed or were terminated, 53 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
141 of 454 have an industry lead sponsor. The 10 most frequent:
Guy's and St Thomas' NHS Foundation Trust is the lead sponsor of 295 studies on the registry; 80 are open to participants now.
Guy's and St Thomas' NHS Foundation Trust has 2 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
29 of the studies in Obesity with a site in United Kingdom that are under way reach primary completion within a year, 10 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
Add all 29 to your calendar (.ics) → With an account.
Among the 454 studies in Obesity with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a real-world study. The purpose of this research is to explore whether a new National Institute for Health and Care Excellence (NICE)-approved digital weight-management model of care can improve health service delivery and address the Quintuple Aim of Healthcare (health outcomes, cost, patient and clinician experience, and health inequalities), for individuals living with obesity accessing National Health Service (NHS) Tier 3 weight-management services.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study participants who receive 12 months of digital weight management services delivered through a smartphone app.
Other: Digital Weight Management Programme
Study participants who receive 12 months of digital weight management services delivered through a smartphone app
Other: Digital Weight Management Programme
Patients who receive standard of care weight management services
Patients who receive standard of care service after discharge from standard of care weight management services
Digital Weight Management Programme
Percentage of weight change at 12 months
Time frame: Baseline and 12 months
Quality of Life as a measure to determine cost-effectiveness
Quality of Life will be measured using the European Quality of Life 5 Dimensions 5 Level (EQ-5D-5L) questionnaire
Time frame: Baseline and 12 months
Feasibility of implementing the intervention into Tier 3 weight management pathways
This will be assessed through qualitative interviews with participants in the Sub-study.
Time frame: Once
Acceptability of implementing the intervention into Tier 3 weight management pathways
This will be assessed through qualitative interviews with participants in the Sub-study.
Time frame: Once
Uptake of the intervention
Time frame: 12 months
Retention in the intervention programme
Time frame: From enrolment until the end of the intervention at 12 months /withdrawal/dropout
Success in the intervention programme
This will be assessed as clinically significant percentage in weight change of greater than or equal to 5 percent.
Time frame: From enrolment until the end of the intervention at 12 months
Economic measurements - Quality of Life Years
Quality-Adjusted Life Years (QALYs) associated with weight loss, calculated from the scores on the European Quality of Life 5 Dimensions Level questionnaire (EQ-5D-5L)
Time frame: Baseline, 6 months, and 12 months
Economics measurements - Resource Use
Resource use covering primary and secondary care services within the National Health Service (NHS)
Time frame: From enrolment to the end of the intervention at 12 months
Economics measurements - Unit costs
Unit costs obtained from standard sources such as NHS reference costs and Personal Social Services Research Unit's unit costs for health and social care.
Time frame: From enrolment to end of intervention at 12 months
Economics measurements - Costs between intervention group and standard care group
Costs between intervention group and standard care group with be compared
Time frame: From enrolment to end of intervention at 12 months
Patient reported outcomes - alcohol use
This will be assessed using a self-reported questionnaire - Alcohol Use Disorders Identification Test (Audit) / scale ranges 0 - 40 / 0=low risk, 20 or more = possible alcohol dependence
Time frame: At Baseline, 6 months, and 12 months
Patient reported outcomes - patient health
This will be assessed using the self-reported Patient Health Questionnaire-4 (PH-4) / Score range 0 - 12) / Score of 3 or higher further assessment for depression \&/or anxiety recommended
Time frame: Baseline, 6 months, 12 months
Patient reported outcomes - eating pattern
This will be assessed using the self-reported Three-Factor Eating Questionnaire / Score range 1 - 4 for each question / scores are summated into scale scores for cognitive restraint, uncontrolled eating, and emotional eating.
Time frame: Baseline, 6 months, 12 months
Patient reported outcomes - binge eating
This will be assessed using the self-reported Binge Eating Scale (BES) questionnaire / Score range 0 - 46 / 17 or lower = low binge-eating, 18-26 = mild to moderate binge-eating, 27 or higher = severe binge-eating
Time frame: Baseline
Patient reported outcomes - physical activity
This will be assess using the self-reported General Practice Physical Activity Questionnaires / Scoring is: Inactive, Moderately inactive, Moderately active, or Active
Time frame: Baseline if required per clinician assessment
Sub-group analyses- Use of glucagon-like peptide (GLP-1) agonists
Participant use (never/commenced during study/used throughout) of GLP-1 agonsits will be assessed
Time frame: From enrolment until the end of intervention at 12 months
Sub-group analyses - Adherence
Participant adherence to the intervention will be assessed
Time frame: From enrolment until drop-out, withdrawal, or end of intervention at 12 months
Sub-group analyses - Comorbidities
Obesity-related medical comorbidities will be assessed
Time frame: From enrolment until end of intervention at 12 months
Sub-group analyses - Social demographics
Participant social demographics such as sex, ethnicity, age, and Index of Multiple Deprivation (IMD) will be assessed.
Time frame: At enrolment
Clinical measures - height
Height in metres will be assessed as part of the clinical measures analysis
Time frame: Baseline
Clinical measures - blood pressure
Self-reported blood pressure will be assessed as part of the clinical measures analysis
Time frame: Baseline, 6 months, and 12 months
Clinical measures - Body Mass Index
Body Mass Index (BMI) will be assessed from self-reported weight in kilograms divided by height in metres squared, as part of the clinical measures analysis.
Time frame: Baseline, 6 months, and 12 months
Clinical Measures - waist circumference
Self-reported waist circumference in centimetres will assessed as part of the clinical measures analysis
Time frame: Baseline, 6 months, 12 months
Plan to share: Yes — IPD will be shared on reasonable request.
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Nov 2027, 23 months after the start.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 23 months is close to that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Guy's and St Thomas' NHS Foundation Trust →